Enliven Therapeutics Ownership & Insider Activity

Enliven Therapeutics (ELVN) institutional and insider ownership, recent insider transactions and ownership breakdown.

Insiders own 0.5% of shares outstanding. Institutional investors hold 53.6%. Over the past 90 days, insiders made 4 sales worth $1.4M.

Shares Outstanding

71.438M

Shares Float

49.020M

Insider Shares Owned

377.020K

Insider % Owned

0.5%

Institutional Shares Held

39.250M

Institutional % Held

53.6%

Ownership Breakdown

Net Insider Activity by Month

Purchases (90d)

Sales (90d)

$1.4M total

Net Activity

Net Selling

Net Value (90d)

-$1.4M

Enliven Therapeutics Insider Transactions (Last 6 Months)

Date	Insider	Title	Type	Shares	Price	Value
Sep 17, 2026	Benjamin Hohl	CHIEF FINANCIAL OFFICER	SELL	2.036K	$32.60	$244K
Sep 17, 2026	Louise Helen Collins	CHIEF MEDICAL OFFICER	SELL-OPTIONS	—	$26.42	$239K
Aug 17, 2026	Benjamin Hohl	CHIEF FINANCIAL OFFICER	SELL	6.018K	$58.58	$353K
Aug 17, 2026	Louise Helen Collins	CHIEF MEDICAL OFFICER	SELL-OPTIONS	—	$30.53	$281K
Aug 4, 2026	Mika Derynck	—	SELL-OPTIONS	—	$35.53	$7.8M
Jul 17, 2026	Benjamin Hohl	CHIEF FINANCIAL OFFICER	SELL	4.946K	$27.56	$314K
Jul 17, 2026	Louise Helen Collins	CHIEF MEDICAL OFFICER	SELL-OPTIONS	—	$27.58	$251K
Jul 6, 2026	Anne Lori Kunkel	—	SELL	10.000K	$50.49	$505K
Jun 22, 2026	ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC	10% OWNER	SELL	860.123K	$45.36	$39.0M
Jun 17, 2026	Benjamin Hohl	CHIEF FINANCIAL OFFICER	SELL-OPTIONS	—	$23.14	$249K
Jun 17, 2026	Louise Helen Collins	CHIEF MEDICAL OFFICER	SELL-OPTIONS	—	$23.14	$207K
Jun 15, 2026	ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC	10% OWNER	SELL	281.408K	$45.02	$12.7M
Jun 5, 2026	Anne Lori Kunkel	—	SELL	10.000K	$34.54	$345K
May 18, 2026	Louise Helen Collins	CHIEF MEDICAL OFFICER	SELL-OPTIONS	—	$21.14	$187K
Apr 17, 2026	Louise Helen Collins	CHIEF MEDICAL OFFICER	SELL-OPTIONS	—	$25.08	$226K